Thursday, November 16, 2017 - 16:45
Industrial Solutions
PROTON THERAPY AND OTHER ACCELERATORS PROJECTS ON TRACK, DOSIMETRY SALES UP 20%, GUIDANCE REITERATED Olivier Legrain, Chief Executive Officer of IBA commented: “Our performance in the third quarter continues to reflect the challenges reported at the time of our half year results. However, the proton therapy market remains buoyant and demand for IBA’s leading offering is high, with over five systems in the last stages of negotiation. Revenue recognition from our ongoing projects is on track and Dosimetry and Services continue to demonstrate good revenue and backlog growth. Furthermore, the collaborations announced with Elekta and Vinci Construction during the quarter give us an even more competitive and attractive offering for our customers worldwide. “We continue to build upon our world leading position in proton therapy, our production expansion remains on track and will assist us in our aim to bring the most technologically advanced and commercially attractive offering to established and growing markets globally.”
Back to news